We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

87 hedge funds and large institutions have $317M invested in Phathom Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 25

7% more call options, than puts

Call options by funds: $133K | Put options by funds: $124K

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

5% less capital invested

Capital invested by funds: $334M → $317M (-$17.8M)

7% less funds holding

Funds holding: 94 → 87 (-7)

9.25% less ownership

Funds ownership: 77.04% → 67.79% (-9.3%)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
87
Holders Change
-7
Holders Change %
-7.45%
% of All Funds
1.4%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
30
Reduced
25
Closed
15
Calls
$133K
Puts
$124K
Net Calls
+$9K
Net Calls Change
-$1.91M

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$4.3M
2
NM
Newtyn Management
New York
+$1.73M
3
BlackRock
BlackRock
New York
+$1.56M
4
Walleye Capital
Walleye Capital
New York
+$1.5M
5
Invesco
Invesco
Georgia
+$1.44M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$26.8M
2
6CM
683 Capital Management
New York
-$3.24M
3
UOC
UBS O'Connor
Illinois
-$1.71M
4
HF
HRT Financial
New York
-$585K
5
Millennium Management
Millennium Management
New York
-$558K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
$130K +$6.92K +671 +6%
State Board of Administration of Florida Retirement System
52
State Board of Administration of Florida Retirement System
Florida
$126K -$50.2K -4,870 -30%
Deutsche Bank
53
Deutsche Bank
Germany
$122K +$1.57K +152 +1%
AQR Capital Management
54
AQR Capital Management
Connecticut
$113K +$104K +10,046 New
SCA
55
STALEY CAPITAL ADVISERS
Pennsylvania
$112K – – –
Barclays
56
Barclays
United Kingdom
$99.6K +$81.5K +7,903 +810%
Legal & General Group
57
Legal & General Group
United Kingdom
$83.3K – – –
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$46K +$39.8K +3,859 +1,378%
AB
59
Amalgamated Bank
New York
$40K – – –
QT
60
Quantbot Technologies
New York
$32.8K -$4.12K -400 -12%
Citadel Advisors
61
Citadel Advisors
Florida
$19.7K +$18.1K +1,753 New
MLICM
62
Metropolitan Life Insurance Company (MetLife)
New York
$15.7K – – –
AIP
63
Ameritas Investment Partners
Nebraska
$13.9K – – –
Citigroup
64
Citigroup
New York
$12.7K -$1.19K -115 -9%
USCWA
65
U.S. Capital Wealth Advisors
Texas
$11.2K +$10.3K +1,000 New
HNB
66
Huntington National Bank
Ohio
$10.4K -$41 -4 -0.4%
Canada Life
67
Canada Life
Manitoba, Canada
$10K – – –
UBS Group
68
UBS Group
Switzerland
$8.92K +$1.72K +167 +27%
Fidelity Investments
69
Fidelity Investments
Massachusetts
$7.8K -$5.36K -520 -43%
TRCT
70
Tower Research Capital (TRC)
New York
$5K -$40.9K -3,965 -89%
CUAMC
71
China Universal Asset Management Company
China
$4.75K +$577 +56 +15%
CG
72
Cutler Group
California
$4K – – –
TWM
73
Tradition Wealth Management
Minnesota
$4K – – –
US Bancorp
74
US Bancorp
Minnesota
$3.92K -$619 -60 -15%
QCG
75
Quadrant Capital Group
Ohio
$2.38K – – –
1 2
3
4

PHAT Hedge Fund Activity: Q4 2022 in Review

87 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2022, worth a combined $317M — down 5.3% from $334M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PHAT and 9 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 30 added.

The largest buyer was Opaleye Management, opening a new position worth an estimated $4.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $26.8M sold.

  • 87 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2022, down from 94 in Q3 2022.
  • Funds reported $317M of Phathom Pharmaceuticals stock for Q4 2022, down 5.3% quarter-over-quarter.
  • 9 funds opened new Phathom Pharmaceuticals positions in Q4 2022 and 15 closed out, a net change of -6 holders.
  • The largest Phathom Pharmaceuticals buyer in Q4 2022 was Opaleye Management, an estimated $4.3M added.
  • The largest Phathom Pharmaceuticals seller in Q4 2022 was Deerfield Management, an estimated $26.8M sold.

Based on aggregated 13F filings for Q4 2022.